Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2024 (Fiscal Q2 2025)
Business Overview: Accuray designs, develops, and sells advanced radiosurgery and radiation therapy systems (CyberKnife and TomoTherapy platforms) for cancer treatment. The company operates globally with significant exposure to international markets, particularly China, where it maintains a 49% joint venture (JV) with CNNC High Energy Equipment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|---|
| Net Revenue | $116,174 | $217,719 | $211,130 |
| Gross Profit | $41,892 | $76,361 | $75,395 |
| Gross Margin | 36.1% | 35.1% | 35.7% |
| Operating Income (Loss) | $4,707 | $2,558 | $(1,751) |
| Net Income (Loss) | $2,537 | $(1,417) | $(12,590) |
| Diluted EPS | $0.02 | $(0.01) | $(0.13) |
| Cash and Cash Equivalents (Dec 31, 2024) | $62,584 | ||
| Total Debt (Dec 31, 2024) | $175,513 (Net Carrying Amount) | ||
| Order Backlog (Dec 31, 2024) | $463,056 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 8% ($8.9M) for the quarter and 3% ($6.6M) for the six-month period compared to the prior year. This was driven by higher shipment volumes in China (up 54% QoQ), Japan (up 41%), and Asia Pacific (up 61%), partially offset by declines in the Americas (down 28%) and EIMEA (down 11%).
- Profitability: The company returned to profitability for the quarter with $2.5M net income, compared to a $9.6M loss in the prior year quarter. For the six-month period, the net loss narrowed significantly to $1.4M from $12.6M.
- Operating Expenses: Total operating expenses decreased 7% ($2.7M) for the quarter and 4% ($3.3M) for the six-month period, primarily due to lower headcount and severance costs from a 2024 restructuring initiative.
- Joint Venture Impact: Income from the China JV increased significantly to $1.6M for the quarter (from a $0.4M loss), contributing to the improved bottom line.
- Backlog: Order backlog decreased to $463.1M from $492.1M in the prior year, impacted by age-outs ($53.4M) and currency impacts, despite gross orders of $132.1M for the six-month period.
Guidance, Outlook, and Risks
- Outlook: Management expects inflation, supply chain challenges, and logistics costs to continue adversely affecting gross margins and cash flow through fiscal year 2025. Reduced budgets and longer installation timelines in the U.S. are expected to impact net revenue through fiscal year 2026.
- Liquidity: The company believes it has sufficient cash resources to fund operations for at least the next 12 months. However, it recently amended its Credit Agreement (Fourth Amendment) to add a minimum liquidity covenant and reduce available revolving commitments to $20.0M.
- Debt Covenants: The company is unable to predict with certainty its ability to maintain compliance with financial covenants (Fixed Charge Coverage Ratio and Senior Net Leverage Ratio) due to macroeconomic uncertainty. Failure to comply could accelerate debt maturity.
- Internal Controls: The company disclosed material weaknesses in internal controls related to its ERP system implementation. One weakness regarding manual journal entries was remediated in Q2; remediation for inventory cycle count controls is ongoing.
- Geopolitical Risks: Significant risks include U.S.-China tensions, tariffs, the Russia-Ukraine conflict, and the impact of the China anti-corruption campaign on the JV and broader operations.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to meet the new minimum liquidity covenant and other financial ratios under the amended Credit Agreement.
- U.S. Market Trends: Monitor the duration and severity of reduced capital deployment and installation delays in the U.S. market, which management expects to persist through 2026.
- China JV Performance: Assess the sustainability of the JV's revenue growth and the realization of deferred gross profit from intra-entity sales.
- Internal Control Remediation: Confirm the timeline for fully remediating the remaining material weakness regarding inventory cycle counts.
- Backlog Conversion: Track the rate of backlog conversion to revenue, noting the high risk of cancellations and age-outs in the current economic environment.